Dividend Growth Investing and chit chat. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Dividend Growth Investing and chit chat.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: rnsmth	1/23/2022 8:38:31 AM
	of 2146

Jan. 23, 2022 7:50 AM ETGlaxoSmithKline plc (GSK), ULPFE, MDLZ, PGBy: Joshua Fineman, SA News Editor4 Comments Activist hedge fund Trian Partners is said to take a stake in Unilever (NYSE:UL) as shareholder pressure mounts after a failed attempt to acquire GlaxoSmithKline's (NYSE:GSK) consumer healthcare business. Trian, led by Nelson Peltz, accumulated a stake in the consumer goods company, according to an FT report. The size of the stake or when Trian began building it wasn't known. Peltz and Trian have had previous experience with consumer packaged goods company and last April Peltz stepped down from the board of Procter & Gamble (NYSE:PG) four years after taking a stake and tussling with the company over its strategy. Trian also previously had a stake in Mondelez (NASDAQ:MDLZ). Unilever shares plunged 14% on Tuesday in U.S. trading as investors reacted to its bid for GlaxoSmithKline’s consumer unit. The business under consideration was formed in 2018 from the combination of the consumer assets of GSK and Pfizer (NYSE:PFE). News of the Trian stake in Unilever comes after the company earlier this week said it wouldn't increase its GBP50B ($68b) bid for the GSK consumer health unit.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next